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Summary
For viruses to establish persistent infections in their hosts, they must possess some mechanism
for evading clearance by the immune system. When inoculated into adult immunocompetent
mice, wild-type lymphocytic choriomeningitis virus (LCMV ARM) induces a CD8+-mediated
cytotoxic T lymphocyte (CTL) response that clears the infection within 7-14 d (CTL+[P-1).
By contrast, variant viruses isolated from lymphoid tissues of persistently infected mice fail to
induce a CTL response and are thus able to establish a persistent infection in adult mice (CTL -
[P+l). This report compares the interaction of CTL+(P - ) and CTL- (P+) viruses with cells of
the immune system . Both types of virus initially bind to 2-4% of CD4+ and CD8+ T
lymphocytes and replicate within cells of both subsets. The replication of CTL - (P+) and
CTL+(P-) viruses in lymphocytes in vivo is similar for the first 5 d after initiating infection.
Thereafter, in mice infected with CTL - (P+) variants, lymphocytes retain viral genetic
information, and infectious virus can be recovered throughout the animals' lives. In contrast,
when adult mice are infected with wild-type CTL+(P- ) LCMV ARM, virus is not recovered
from lymphocytes for >7 d after infection. A CD8+-mediated anti-LCMV CTL response is
induced in such mice. Clearance of infected lymphocytes is produced by these LCMVspecific
CTLs, as shown by their ability to lyse lymphocytes expressing LCMV determinants in vitro
and the fact that depletion of CD8 + lymphocytes before infection with CTL+(P-) viruses results
in levels of infected lymphocytes similar to those found in undepleted CTL- (P+)-infected mice.
Hence, CTLmediated lysis of T lymphocytes carrying infectiousvirus is a critical factor determining
whether virus persists or the infection is terminated.
A number ofdiverse viruses, including EBV, cytomegalo-
virus, varicella-zoster virus, herpes simplex virus, rubella
virus, measles virus, hepatitis B virus, human T cell leukemia
viruses, and HIV, are known to cause persistent infections
in man, and produce diseases of medical significance (1, 2).
Establishment of persistent virus infection in vivo requires
that the virus must persist within cells. To achieve this, a
lytic virus life-cycle must change to a nonlytic one. In addi-
tion, the infected cells must survive in the host, hence the
host immune system must be evaded (reviewed in references
3 and 4). To achieve the latter, viruses may: (a) avoid recog-
nition by the immune system, either by downregulating their
protein expression, as exemplified by herpes virus latency (5-7),
and by decreased expression of viral proteins on the surface
of measles virus-infected cells (8, 9) ; or by downregulating
MHC expression as occurs with certain adenovirus subtypes
(10-12) and with cytomegalovirus (13); and/or (b) directly
or indirectly interfere with cells of the immune system so
that they no longer mediate protection (reviewed in refer-
ence 14). Examples of such interference include infection of
monocytes and CD4+ T lymphocytes by HIV resulting in
immunosuppression (15); infection ofCTL and NK cells by
human cytomegalovirus (HCMV)t, which abrogates their
ability to kill HCMVinfected targets (1b); and measles virus
infection ofB lymphocytes and CTL, which aborts both hu-
moral and cell-mediated responses to the virus (17-19).
To understandhow viruses avoid immune surveillance and
persist, we have studied mice infected with lymphocytic cho-
riomeningitis virus (1,CMV). The wild-type Armstrong strain
ofthe virus (LCMV ARM) causes a lifelong persistent infec-
tion, during which viral materials remain in many tissues,
in animals infected in utero or neonatally (20-22). However,
' Abbreviations used in this paper: CNS, central nervous system; HCMV,
human cytomegalovirus; LCMV, lymphocytic choriomeningitis virus; NP,
nucleoprotein.
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mice, it induces a CD8 + -mediated CTL response that, de-
pending on the dose and route of administration, either clears
infectious virus and viral materials from the animal within
7-14 d or leads to central nervous system (CNS) immune
pathology and death (20, 21, 23). Virus recovered from the
brain, liver, or kidneys of persistently infected mice main-
tains the parental CTL+(P - ) phenotype when inoculated
into normal adult mice. By contrast, LCMVvariants isolated
from lymphoid cells of persistently infected mice fail to in-
duce an effective CTL response when inoculated intravenously
into adult animals and thus establish persistent infection
(CTL - [P+J) (24, 25).
Comparison of CTL+(P- ) and CTL - (P+) virus isolates
derived from LCMV ARM and revertants from the CTL -
to the CTL * phenotype, at the molecular level (26, 27) has
shown that a single amino acid change from phenylalanine
to leucine at position 260 of the LCMV glycoprotein GP-1
is associated with the difference in biological phenotype.
Similar results were obtained by Matloubian et al. (28) using
reassortant viruses. How this single amino acid change is as-
sociated with or mediates its effect is not known. However,
it is clear that the defect in the antiviral CTL response occurs
at the induction rather than the recognition level, because:
(a) mapping of the LCMV domains recognized by virus-
specific CTL in a number of different haplotypes has shown
that GP-1 amino acid 260 is not contained within any of the
known epitopes (29-31); (b) the CTL- (P`) phenotype is
not MHC haplotype dependent; (c) cells infected with
CTL - (P+) derivatives of LCMV ARM are recognized by
LCMVspecific CTL from ARM-infected mice just as ef-
ficiently as target cells infected with CTL+(P- ) viruses (32);
and (d) CTL - (P+) viruses can induce CTL responses when
administered at low doses or via the intraperitoneal route.
In this paper, we focus on the interaction of CTL+(P")
and CTL - (P *) viruses with cells of the immune system,
addressing four questions. First, do CTL'(P - ) and CTL-
(P+) viruses bind to T cells equivalently? Second, are binding
and subsequent virus replication limited to a particularT lym-
phocyte subset, or are both CD4+ and CD8+ lymphocytes
involved? Third, are there differences in the progression of
the infection of immune system cells in mice infected with
CTL+(P - ) or CTL - (P+) viruses, and fourth, if so, what is
the mechanism(s) that underlies these differences? We show
here that both types of virus bind with equal efficiency to
lymphocytes of the CD4+ and CD8' subsets, and that this
is reflected in their in vivo tropism early after infection. The
number of infected lymphocytes detected differs thereafter.
This is shown to be a consequence of CTL+(P - ) virus in-
ducing LCMVspecific CTL that remove infected lympho-
cytes, whereas CTL - (P+) virus fails to induce a CTL re-
sponse. Lifelong infection of lymphocytes, cells from which
the CTL - (P+) immunosuppressive variant can be isolated,
occurs. The result is a failure to generate an effective CTL
response, thereby establishing a milieu allowing continuous
viral replication in many tissues and avoidance of immune
clearance.
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Materials and Methods
Virus.
￿
Parental LCMV ARM 53b stock (CTL + [P-]) was ob-
tained from a triple plaque-purified clone subsequently passaged
twice in BHK cells (33) . Clone 13 (a CTL-[P*] variant) was de-
rived from spleen cells of an adult BALB/WEHI mouse in which
a persistent infection had been initiated at birth with ARM 53b
(24). Virus was recovered from lymphocytes by infectious center
assay(34, 35). Plaque-purifiedclone 13 was passaged twicein BHK
cells. The titers of virus stocks were determined by plaque assay
on Vero cells (33).
Mice: Infection and In Vivo Depletion of T Cells.
￿
BALB/WEHI
mice maintained in the closed breeding colony ofthe Research In-
stitute ofScripps Clinic were used for all experiments. They were
infected as adults (6-8 wk old) by intravenous inoculation of 2 x
106 PFU of virus. At this dose, ARM 53b-infected animals
generate a virus-specific CTL response that clears the infection,
whereas clone 13-infected animals fail to mount an effective CTL
response and become persistently infected (24).
In some experiments, mice were depleted of CD8* T cells in
vivo by treatment with a subset-specific rat mAb, YTS 169.4 (36) .
The antibody was partially purified from ascites by ammonium sul-
phate precipitation, dialyzed against PBS, and adjusted to a con-
centration of 10 mg/ml. T cell depletion was achieved by intrave-
nous administration of 0.1 ml of antibody (at 10 mg/ml) on days
-2 and +2 relative to the time of virus infection (day 0). This
treatment results in elimination of 95-98% of CD8* T cells from
the periphery (36).
Mononuclear Cell Preparation and Purification of Lymphocyte
Subsets. PBMC were purified by Ficoll-Hypaque gradient centrifu-
gation of mouse blood, as described (34, 35). Briefly, heparinized
blood was dilutedone in threein PBS, pH 7.2, layered onto an equal
volume ofFicoll-Hypaque solution (Sigma Chemical Co., St. Louis,
MO), and spun at 600 g for 20 min at room temperature. Cells
at the interface were collected, washed in MEM containing 7%
heat-inactivated FCS, and contaminating erythrocytes were removed
by lysis with 0.83% ammonium chloride. After two washes, the
number of viable cells was determined using trypan blue.
Spleens were dispersed by pressing through a wire grid, then
the cells were washed and passed through 45-60-mm nylon mesh
to remove aggregates. Single-cell suspensions of mononuclear cells
were then purified on Ficoll-Hypaque gradients as described above.
To enrich T cells from the total mononuclear cell preparations,
adherent cells and B cells were depleted by panning on anti-Ig-
coated plastic Petridishes using the method described by Wysocki
and Sato (37) . Briefly, goat anti-mouse IgG and IgM (Boehringer
Mannheim Biochemicals, Indianapolis, IN) was diluted to 5 mg/ml
in PBS. Plastic Petri dishes (100 x 15 mm) were coated by incuba-
tion with 10 ml of the anti-Ig solution for 40 min at room temper-
ature. The plates were washed four times with PBS and once with
PBS containing 1% FCS; then cells were added: 2-3 x 10' cells
suspended in 3 ml o£ PBS containing 5% FCS per plate. The plates
were incubated on a level surface at 4°C for 40 min, swirled gently
to redistribute unattached cells, and then incubated for another 30
min. The T cell-enriched, nonadherent cell fraction was collected
by swirling the dish and decanting the supernatant and then washing
the plate once gently with 5-10 ml of PBS containing 1% FCS.
In several experiments, >85-90% of cells obtained were Thy-1* ,
with <10% Ig' cells.
CD4+ and CD8* subpopulations were isolated from the T
cell-enriched preparations by FRCS'* (Becton Dickinson & Co.,
Mountain View, CA) as described (35, 38). CD4* and CD8'
subsets were marked using the subset-specificrat mAbs YTS 191.1(anti-CD4) and YTS 169.4 (anti-CD8) (36). 107 lymphocytes were
incubated with 100 Al of neat hybridoma supernatant at 4°C for
45 min. The cells were washed three times with MEM containing
5% FCS, and incubated for 30 min at 4°C with the second anti-
body: 100 A1 of fluorescein-labeled F(ab')Z mouse anti-rat IgG
(Jackson Labs Inc., West Grove, PA) diluted to 20 mg/ml in PBS
containing 5% FCS. After an additionalthreewashes, flow cytom-
etry was performed on a FACS IV® (Becton Dickinson & Co.).
A minimum of 106 positive cells was collected from each sample.
Cells were sorted so that the purity of each subset exceeded 99%.
This was frequentlyachieved in one sort, but if not, a second sort
with more stringent gates was used to ensure >99% purity.
Binding ofLCMV to Lymphocytes.
￿
Binding of virus to cells was
assayed using biotin-labeled virus as described (39, 40).
Briefly, LCMV was purified by polyethylene glycol precipita-
tion followed by centrifugation at 35,000 rpm for 30 min on a
discontinuous renografingradient (20). Purified virus (1-2 mg pro-
tein/ml) was incubated with N-hydroxysuccinimidiobiotin diluted
to 1 mg/ml in dimethylsulphoxide (39, 40). A 5:1 ratio of virus
to biotin was used. After removing free biotin by dialysis against
PBS, aliquots ofbiotinylated viruswere diluted in RPMI containing
7% FCS, and either used directly or stored at -70'C until re-
quired. Virus infectivity was titered by plaque assay, and only bi-
otinylated virusretaining >50% infectivity was used in experiments.
For the binding assay, varying amounts of biotinylated virus
(0.5-30 mg) were added to single cell suspensions of 106 lympho-
cytes and incubated on ice. After 45 min at 4°C, cells were washed
twice and avidin-PE was added. After another 30-min incubation
on ice, cells were washed, and the maximal amount ofvirus-biotin
bound was determined by FACS® analysis. Specificity of binding
was demonstrated by the ability ofunlabeled virus to block LCMV
biotin binding, and the lack ofbinding ofLCMVbiotin complexes
to two cell lines (RMA and RMAS), which LCMV ARM 53b
is unable to infect.
In several experiments, two-color immunofluorescence was done,
using avidin-PE to identify virus-biotin complexes, and T cell
subset-specific rat mAbs and FITC-labeled anti-rat antibody to mark
T cell subpopulations.
Infectious Center Assay.
￿
As described by Doyle and Oldstone
(34), serial 10-fold dilutions of cells (from 106/well) were plated
on semi-confluent layers ofVero cells grown in six-well plates (Falcon
Labware, Oxnard, CA). After adsorption for 60 min at 37°C, 0.5%
agarose was added. After a 6-d incubation at 37°C, the remaining
cells on the plate were fixed with 10% formaldehyde in PBS and
stained with crystal violet. The results were calculated as the number
of infectious centers per 106 viable mononuclear cells plated.
Freeze-thawing cells before plating on Vero cells failed to release
infectious virus.
CTL Assay.
￿
Virus-specific CTL lysis was quantitated with a
standard "Cr release assay, conditions for which are detailed else-
where (41). Effector cells were lymphocytes prepared by Ficoll-
Hypaque density gradient centrifugation from the spleens of
BALB/WEHI mice infected 7 d earlier by intraperitoneal inocula-
tion of2 x 105 PFU of LCMV ARM. E/T ratios of 100:1, 50:1,
and 25:1 were set up. The H-2d-restricted, LCMVspecific CTL
clone HD-8 was also used as an efFector cell, at an E/T ratio of
5:1. This clone and the H-2d clone HD-9 recognize the LCMV
nucleoprotein (NP) epitope amino acids 119-127 (42). The fibro-
blast cell lines BALB Cl 7 (H-2d) and MC57 (H-26), CTL clone
HD-9 (H-2d), and a mixed T lymphocyte population prepared
from spleens of H-2d or H-26 mice were used as target cells. In
some experiments, to enable uninfected target cells to be recog-
205
￿
Borrow et al.
nized by LCMVspecific CTL, the LCMV NP peptide amino acids
116-129 were used to coat the target cells. Peptide was added to
the assay medium at a concentration of 200 ng/ml (42).
All samples were run in triplicate, and the assay time was 5 h.
Results are expressed as the percent LCMVspecific lysis, calculated
as: 100x (experimental release - spontaneous release)/(maximum
release - spontaneous release). The variance among triplicate
samples was <10%.
Results
CTL -(P') and CTL'(P -) Viruses Bind Equivalently both
to Unfractionated Mononuclear Cells and to Specific CD4' and
CD8' T LymphocyteSubsets. Initially, binding of the immu-
nosuppressive viral variant LCMV ARM done 13 (CTL - [P'])
and the wild-type parental ARM 53b (CTL' [P-]) virus to
mononuclear cells obtained from the spleen and peripheral
blood was analyzed. As seen in-Fig. 1 A, the avidin-PE con-
jugate alone did not bind to mononuclear cells. However,
addition of either CTL- (P') or CTL'(P - ) biotinylated
virus before avidin-PE resulted in a significant and equiva-
lent extent of binding between mononuclear cells and LCMV
(Fig. 1, B and C), in six independent experiments.
Next, to determine whether CTL - (P+) and CTL'(P-)
viruses bound specifically to CD4' and/or to CD8' lym-
phocyte subsets, mAbs directed against either CD4' (Fig.
1 D) or CD8' (Fig. 1 G) lymphocytes and a FITC
fluorochrome were used to identify these two subsets in
FACS®. Double immunofluorescence then marked the binding
of virus to these lymphocyte subsets. As shown in Fig. 1,
equivalent numbers of CD4' cells bound both viruses: in
this experiment, 2 .6% of CD4' cells bound CTL - (P')
virus (Fig. 1 F) and 2.4% bound CTL'(P - ) virus (Fig. 1
E). In three additional experiments similar results were noted:
a range of 2.6% ± 0.5 CD4' cells bound CTL -(P') virus,
while 3.3% ± 0.6 of CD4' cells bound CTL'(P - ) virus.
CD8' lymphocytes also bound equivalently to CTL - (P')
(Fig. 1 I) and CTL' (P - ) (Fig. 1 H) viruses: in repeated ex-
periments binding ranged from 0.7 to 3.4%.
Similar results were obtained regardless of whether the cells
used were obtained from peripheral blood or spleens, or
whether lymphocyte subsets were identified with PE and virus
binding by avidin FITC or vice versa.
Progression ofProductive Infection ofMononuclear Cells after
Infection of Mice with CTL - (P') and CTL'(P -) Viruses.
Having ascertained that CTL - (P') and CTL'(P - ) viruses
bind equivalently to total mononuclear cells and T lympho-
cytes of both the CD4' and CD8' subsets in vitro, we
went on to investigate their ability to productively infect these
cells. Because it proved difficult to infect CD4' or CD8'
lymphocytes in vitro, viral replication was studied in vivo.
Fig. 2 illustrates that both CTL - (P') and CTL'(P-)
viruses could replicate in mononuclear cells from the spleens
and peripheral blood ofmice infected intravenously as adults,
as determined by infectious center assay.
CTL - (P') and CTL'(P - ) viruses infected similar num-
bers of mononuclear cells (from either spleen or peripheral
blood) during the first 3 d after inoculation. The number1a
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Figure 1 . LCMV (both the parental
virus ARM 53b [CTL'(P - )] and the
clone 13 immunosuppressive variant
[CTL -(P')]) binds to mononuclear cells
and to T lymphocytes of the CD4' and
CD8' subsets . Binding is equivalent
(percent binding given in the upper
and/or lower right hand panels) for
CTL*(P- ) and CTL -(P') viruses .
Ficoll-purified lymphocytesfrom spleens
of 8-wk-old BALB/W mice were in-
cubated first withbiotinylatedLCMV and
then with avidin-PE . Concurrently, lym-
phocyte subsets were marked with mAbs
and FITC. Double-labeled cells were
studiedby FACS®. For each sort, a square
divided into four segments is shown. The
three sets of controls (R, D, and G) rep-
resent the mononuclear cell population
and CD4' and CD8 * subsets in the ab-
sence ofbiotinylated virus. (B, E, and H)
binding ofCTL+(P- ) virus ; (C, F, and
n binding of CTL-(P+) virus . Each
upper left square records the CD4' or
CD8' lymphocytes not binding bio-
tinylated virus, and the upper right square
depicts the CD4' or CD8' lympho-
cytes that do bind biotinylated virus.
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Figure 2 .
￿
Infectious centers in total mononuclear cell
populations from spleens andperipheralblood after infec-
tion of mice with CTL-(P') or CTL'(P - ) virus .
Groups of 12 2-mo-old BALB/W mice were infected in-
travenously with 2 x 106 PFU of either clone 13 (®),
a CTL- (P') immunosuppressive viral variant ; or LCMV
ARM 53b (0), the parental virus (CTL' [P - ]) it was de-
rived from . Three animals/group were killed at the indi-
cated times after infection . Mononuclear cells were iso-
lated from the peripheral blood and spleen of individual
animals by Ficoll-Hypaque density gradient centrifuga-
tion . The number of infectious centers in each cell prepa-
ration was then determined . Results are expressed as logio
infectious centers/10 6 viable cells plated.
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Figure 3.
￿
Kinetics ofinfectious centers in PBMC ofmiceinfected with
CTL -(P+) virus. BALB/W mice were infected intravenously with 2 x
106 PFU of LCMV clone 13 and, at the indicated times post-infection,
four or more animals were bled and PBMC prepared by Ficoll-Hypaque
density gradient centrifugation. The numbers of infectious centers were
determined and the results expressed as logto infectious centers/106 viable
cells plated.
of infectious centers in CTL -(P+) infected mice remained
relatively constant over the next 7 d, but in contrast, the
number of infectious centers in mice infected with CTL+
(P - ) virus fell to an undetectable level by day 7 and there-
after (data shown up to day 10 only in Fig. 2) .
Since the number of splenic mononuclear cells from
CTL - (P+) virus-infected mice scoring as infectious centers
Mice infected with
CTL+(P-) virus
e
￿
Day 3
￿
Day 5
￿
Day ?
￿
Day 3
￿
Day 5
Time Post-Infection
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Mice infected with
CTL-(P+) virus
remained high for the first 10 d after infection (Fig. 2), the
kinetics of infectiouscenters were followed over a 200-4period.
As shown in Fig. 3, the number ofinfectious centers increased
for the first 7 d, peaking at day 7-8, and decreasing there-
after to <102 infectious centers/106 cells, a level that was
maintained throughout the 200-d period examined.
CD4+ and CD8+ T Cell Subsets Are Infected In Vivo by
both CTL -(P+) and CTL+(P-) Viruses. To look specifically
at the infection of T lymphocytes of the CD4+ and CD8+
subpopulations, these cells were enriched to >99% purity
from the spleens of infected animals using mAbs and FRCS®,
and analyzed by infectious center assays. Fig. 4 illustrates that
T cells of both the CD4+ and CD8+ subpopulations repli-
cated CTL - (P+) and CTL+(P-) virus. As observed with
the total mononuclear cell population (Fig. 2), CD4+ and
CD8 + T lymphocytes obtained from CTL + (P - )-infected
mice scored as infectious centers only in the early phase (up
to day 5) of infection, and became free from virus by 7 d
after the initiation of infection. Again, in contrast, CTL -
(P+)-infected mice failed to have cleared virus from their
CD4+ and CD8+ T cells 7 d after infection.
A Specific Anti-LCMV CD8+ CTL Response Generated
after CTL+(P') Virus Inoculation Causes the Decrease in Infec-
tious Center. 3 d after the inoculation of mice with either
CTL -(P+) or CTL+(P - ) viruses, similar numbers of both
CD4+ and CD8+ T lymphocytes were infected, but a differ-
ence in the subsequent course of viral clearance (Figs. 2 and
4) was observed. The decrease in the level of infected lym-
phocytes in CTL+(P- )-infected animals could be due to ei-
ther: (a) the infection being selflimiting, perhaps because
only a subset of T cells are susceptible to infection, and once
these have been lysed, no other lymphocytes are available for
infection; or (b) virus-specific CD8+ CTLs induced by
CTL+(P') virus clearing the infection by lysing lympho-
cytes expressing viral determinants.
To distinguish between these two possibilities, mice were
depleted of CD8+ T cells, infected with ARM 53b (CTL+
[P - J), and the number of infectious centers in splenic
mononuclear cells was compared with those in undepleted
CTL+(P- )- and CTL - (P+)-infected mice. As shown in Fig.
Figure 4. Infectious centers in CD4+ and CD8+
splenic T lymphocyte subpopulations from mice infected
with CTL-(P+) or CTL+(P- ) viruses. Groups of 12
BALB/W mice were infected intravenously with 2 x 106
PFU ofvirus andat theindicated times, four animals/group
were killed and their spleens pooled. Spleen cell suspen-
sions were prepared, and mononuclear cells isolated by
Ficoll-Hypaque density gradient centrifugation. An ali-
quot ofeach cell suspension was kept on ice, andpurified
populations of CD4+ and CD8+ T lymphocytes were
isolated from the remaining cells by panning on anti-Ig-
coatedplastic plates followed by FITC staining with subset-
specific mAbs and FACS8. The CD4+ and CD8+ lym-
phocytepopulations obtained were >99% pure by FAGS®
analysis. The number of infectious centers in the starting
mononuclear cell preparation (0) and the CD4+ (0)
Day 7
￿
and CD8+ (0) selected populations were then deter-
mined, and are expressed as logto infectious centers/106
viable cells plated.Figure 5.
￿
Infectious center levels in splenic mononuclear cells from
CD8+-depleted mice 7 d after infection with CTL+(P-) virus. Groups
consisted of (a) BALB/W mice infected intravenously with 2 x ,106 PFU
ofCTL+(P- ) virus; (b) BALB/W mice similarly infected with CTL-(P+)
virus; and (c) mice depleted of CD8+ lymphocytes by two intravenous
injections of a CD8+-specific rat mAb, YTS 169.4, on days -2 and +2
relative to the day ofinfection (day 0),which were infected intravenously
with 2 x 10 6 PFU of CTL+(P-) virus . 7 d after infection, splenic
mononuclear cells were prepared from individual animals, and infectious
centers assayed and expressed as loglo infectious centers/106 viable cells
plated .
5, the CD8+-depleted CTL+(P - )-infected mice had levels
of infectious centers similar to those found in CTL- (P+)-
infected animals, indicating that CD8+ CTLs control the
infection of lymphocytes in CTL+(P - ) virally infected
animals.
Final experiments established that LCMVspecific CTLs
directly lysed lymphocytes expressing LCMV epitopes (Table
1) . The LCMVspecific Ld-restricted CTL clone HD-8
recognizes theLCMV NP epitope 119-127, as do >96% of
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CTL generated in the spleen after a primary infection of
H-2d mice by LCMV . Both this CTL clone and a polyclonal
population of primary CTLs lysed syngeneic (H-2d) spleen
T cells coated with theLCMV .NP peptide. However, acti-
vated LCMVspecific CTL clones were resistant to CTIr
mediated lysis.
Discussion
This paper compares the biology of a viral variant, CTL'
(P+), that induces immunosuppression and allows the estab-
lishment of life-long persistence, with its parental virus,
CTL+(P - ), which generates the appropriate immune re-
sponse required to terminate acute infection, clear virus, and
thereby prevent persistence. Thekey molecular difference be-
tween the CTL+ (P - ) virus LCMV ARM 53b and its
CTL-(P+) variant, LCMV clone 13, has recently been
shown to be an amino acid change from phenylalanine to
leucine at position 260 in GP-1 (27, 28). This mutation occurs
close to the putative cleavage site where GP-1 and GP-2 are
generatedfrom theprecursor GP-C (43, 44), suggesting that
an event in processingmaybe important . However, how this
amino acid change affects the CTLinducing ability of the
virus is unknown.
We have examined the interaction of these viruses with
lymphocytes . CTL+(P - ) virus binds to both CD4+ and
CD8+ murine T lymphocytes, and both subsets areproduc-
tively infected in vivo . Infectious progeny are made only during
the first week after infection; by day 7 after infection, lym-
phocytes from such infected mice no longer score as infec-
tious centers. This is becauseLCMVspecific CD8+ CTL are
generated after CTL+(P - ) inoculation and these effectar
cells lyse lymphocytesexpressing viral epitopes. The evidence
S1Cr release assay to assess the ability of LCMV-specific CTL to lyse lymphocyte targets expressing LCMV epitopes . LCMV ARM NP amino acids
116-129 contains the immunodominant H-2d (Ld-restricted) epitope recognized by H-2d BALB/c mice (42) . This sequence is identical for CTL*
(P- ) and CTL-(P+) isolates ofLCMV ARM viruses . Effectar cells were either a splenic mononuclear cell preparation from H-2d (BALB) mice primed
7 d previously with 2 x 106 PFU LCMV ARM 53b intravenously or a H-2d CTL clone (HD-8) that specifically recognizes LCMV NP 116-129.
S'Cr release was measured after a 5-h lysis period; the results shown are the percent specific S'Cr release : 100 x (sample release - spontaneous
release)/(maximum release - spontaneous release) .
" Percent specific S'Cr released . Value reflects the mean of triplicate samples. Variance was <10% .
Table 1 . LCMV-specific CTL Lysis of Lymphocyte Targets
Effectars
Day 7 primary H-2d CTL
H-2d CTLs clone HD-8
Target cells (E/T ratio 100:1) (E/T ratio 5:1)
LCMV-infected BALB Cl 7 97* 85
Uninfected BALB Cl 7 Nil Nil
Uninfected BALB Cl 7 + 40 mg/well NP 116-129 90 50
Uninfected H-2d spleen T cells + 40 mg/well NP 116-129 17 23
Uninfected H-26 spleen T cells + 40 mg/well NP 116-129 Nil Nil
H-2d CTL clone HD-9 Nil Nil
H-2d CTL clone HD-9+ 40 mg/well NP 116-129 Nil Nilfor this derives from experiments showing that CTL+(P- )-
infected mice depleted of CD8+-bearing lymphocytes fail to
clear virus (Fig. 5) and that CD8+ LCMVspecific CTL can
lyse syngeneic lymphocytes expressing the appropriate viral
epitope (Table 1). Thus, the clearance of lymphocytes con-
taining virus occurs as a result oflysisby virus-specific MHC-
restricted CD8+ CTL rather than as a consequence of di-
rect lysis by LCMV of mononuclear cells it infects. Hence,
once CD8+ effector cells are removed from virally infected
mice, the numbers of LCMVinfected lymphoid cells are
equivalent after infection with CTL+(P -) or CTL - (P+)
viruses. This observation explains why wild-type virus does
not persist in an immunocompetent host and confirms ear-
lier observations o£ restricted replication of wild-type LCMV
in lymphocytes during the first week afterinfection (34). The
finding that infected lymphocytes are cleared in vivo as a re-
sult of lysis by virus-specific CD8 + CTLs is of interest be-
cause of the previous assumption that T lymphocytes, in par-
ticular CD8+ CTL, are resistant to CTL lysis (45, 46).
Zalman et al. (47) described a homologous restriction factor
within CTL believed to render them resistant to lysis by auto-
logous CTL. Our results indicate that CTL can lyse CD4+
or CD8+ T cells carrying virus, and complement findings
that CTL can lyse virus-infected B cells (48).
The CTL- (P+) immunosuppressive LCMV variant binds
to and replicates in similar numbers of CD4+ and CD8+
lymphocytes for the first 5 d after infection as the CTL+
(P') parental virus (Figs. 1 and 4) . However, in contrast to
CTL+(P -) wild-type virus, by 7 d after the initiation of in-
fection, CTL -(P+) virus aborts the generation of LCMV-
specific CTL, thereby enabling virus to persist in lymphoid
cells over the lifespan of the infected animal (Fig. 3).
Since LCMV ARM (both the CTL+ [P"] parental strain
and the CTL - [P+] immunosuppressive variant) binds to a
small subset ofboth CD4+ and CD8+ lymphocytes in vitro,
apparently only a small population of T cells must express
a receptor for the virus. Our findings on the interaction of
LCMV with T lymphocytes are reminiscent of those of
McGrath and Weissman (49), showing that Moloney leukemia
virus also binds to only a limited number of cells within the
T cell population. The biochemical structure of the LCMV
binding site on lymphocytes or other permissive cells is un-
known, but is under active investigation. Although infec-
tion of murine lymphocytes has been repeatedly demonstrated
in vivo in mice infected as newborns or in utero (34, 35, 50,
51), attempts to bind LCMV- to or infect resting T cells in
vitro were initially unsuccessful (50, 52) . However, recent
studies indicate that binding to and infection of resting and
activated rodent lymphocytes can occur in vitro (53) (Borrow,
P., E. Joly, and M.B.A. Oldstone, unpublished results). The
explanation for these conflicting findings may come from a
recent report (54) documenting the in vitro lymphoid tro-
pism or lack of such tropism in a panel of recently isolated
LCMV variants.
CTL+(P- ) and CTL - (P+) LCMV isolates bind to -2%
of murine CD4+ and CD8+ T lymphocytes in vitro, and
in vivo by day 3 permissively infect (as determined by infec-
tious centers) -0.05% of each subset. Thereafter, mice in-
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fected with CTL-(P+) virus show a peak in lymphoid in-
fectious centers at 7-8 d, followed by a decline to lowerlevels
that are maintained throughout the animals' lives (a 200-d
period of observation). Although both CD4+ and CD8+
cells are equivalently infected during the first week after in-
fection, by 28 d and thereafter, it is the CD4+ lymphocytes
that principally carry virus (35, 38, 51). Why and by what
mechanism a selective decrease in the number of CD8+ lym-
phocytes infected with LCMV occurs is not known. One pos-
sibility is that the balance of complete (infectious virus) to
incompleteviral replication within the CD4+ subset differs
from that in the CD8+ subset. A second possibility is that
the accumulation of viral nucleic acid sequences over time
is more toxic to or lytic in CD8+ than CD4+ T cells.
What then is the cause of the CTL inducing property of
CTL+(P-) virus and the inability to induce CTL of the im-
munosuppressive variant CTL'(P+) virus? The difference
observed in the progression of infection of lymphocytes in
CTL+(P -)- and CTL - (P+)-infected mice is a consequence
ofthe virus's differing abilities to induce a CTL response and
not a lytic property of the virus. The evidence for this con-
clusion is threefold. First, the LCMVspecific CTL response
is CD8 mediated, and depletion of CD8+ cells in vivo con-
verts the kinetics of CTL + (P') virus infection into those of
CTL - (P+) infection. Second, CD8+ LCMVspecific CTL
recognize and lyse T cells expressing viral epitopes. Third,
the replication of CTL+'(P - ) virus within lymphocytic cell
lines in vitro is not associated with cell lysis, and replication
of CTL+ (P -) virus in lymphocytes in vivo is not associated
with virally induced lysis of the cells (Fig. 5). Further, the
transient immunosuppression observed after infection ofmice
with various CTL+(P-) virus strains is also not thought to
be a consequence of virus killing lymphocytes but instead
may be due to disturbance of APC and/or perhaps the induc-
tion of suppressive lymphocyte responses (55-58).
In conclusion, a virus that causes persistent infection on
the basis ofimmunosuppression would be expected to attack
cellsof the immune system and to abort the specific antiviral
immune response(s). These principles have been documented
here and elsewhere for LCMV infection (4, 25, 38, 51). In-
deed, most if not all other viruses that cause persistence also
infect lymphocytes and/or macrophages (reviewed in-refer-
ence 14). As a consequence of infection, cells ofthe immune
system may: (a) be lysed by the virus; (b) become targets of
an immunopathological antiviral immune response; or (c) have
their function impaired by persisting virus (cytopathology
in the absence of cytolysis). Among the better studied ex-
amples are those ofsuppressed Ig synthesis or cytotoxic lym-
phocyte activity induced by measles virus infection of lym-
phocytes (17-19) and immunosuppression associated with
HCMV (16). In nature, HCMV infects lymphocytes and
monocyte/macrophages, and can persist in these cellsin a la-
tent form (59). Lymphocytes isolated from such naturally in-
fected individuals can generate, in vitro, a HCMVspecific
CTL response, except in the presence of recent clinical iso-
lates of virus, which are immunosuppressive (16). CD4+ T
cells are infected in patients with AIDS, and such cells ex-
hibit a defect in their ability to respond to soluble antigenslike tetanus toxoid (60). Similar to events with LCMV, mea-
sles virus, and HCMV infections, the HIVinfected lympho-
cytes showing immune dysfunction are apparently not lysed.
Hence, information is gatheringin many systemsthat viruses
can infect lymphocytes and alter their functions. This
lymphocyte-viral interaction may then explain the ability of
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the virus to persist and/or the presence of functional abnor-
malities associated with a particular viral infection. Thus, it
may well prove profitable to evaluate diseases of unknown
cause that involve defects in immune regulation for a viral
etiology.
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